ANIP
ANI PHARMACEUTICALS INC
Overview
ANI Pharmaceuticals develops, manufactures, and commercializes pharmaceutical products across three business segments: Rare Disease (including the retinal implants ILUVIEN and YUTIQ, and the ACTH therapy Cortrophin Gel), Brands (including products like Inderal and Vancocin), and Generics (a portfolio of over 120 generic drugs).
ANI PHARMACEUTICALS INC is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $1.81B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 6, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0810 Q&A exchanges
- Q4 FY2025Earnings2026-02-278 Q&A exchanges
- Q3 FY2025Earnings2025-11-0710 Q&A exchanges
- Q2 FY2025Earnings2025-08-0812 Q&A exchanges
- Q1 FY2025Earnings2025-05-0912 Q&A exchanges
- Q4 FY2024Earnings2025-02-2817 Q&A exchanges
- Q3 FY2024Earnings2024-11-0810 Q&A exchanges
- Q2 FY2024Earnings2024-08-0911 Q&A exchanges
- Q1 FY2024Earnings2024-05-1015 Q&A exchanges
- Q4 FY2023Earnings2024-02-296 Q&A exchanges
- Q3 FY2023Earnings2023-11-0812 Q&A exchanges
- Q2 FY2023Earnings2023-08-094 Q&A exchanges
- Q1 FY2023Earnings2023-05-0817 Q&A exchanges
- Q4 FY2022Earnings2023-03-0917 Q&A exchanges
- Q3 FY2022Earnings2022-11-099 Q&A exchanges
- Q2 FY2022Earnings2022-08-087 Q&A exchanges
- Q1 FY2022Earnings2022-05-108 Q&A exchanges
- Q4 FY2021Earnings2022-03-1513 Q&A exchanges
- Q3 FY2021Earnings2021-11-018 Q&A exchanges
- Q2 FY2021Earnings2021-08-063 Q&A exchanges
- Q1 FY2021Earnings2021-05-0711 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-06EPS— vs $2.00—Rev— vs ——EODHD
- Q1 FY20262026-05-07EPS$2.05 vs $1.30+57.8%Rev$237.5M vs ——EODHD
- Q4 FY20252026-02-25EPS$2.33 vs $2.04+14.2%Rev$247.1M vs ——EODHD
- Q3 FY20252025-11-06EPS$2.04 vs $1.76+15.9%Rev$227.8M vs ——EODHD
- Q2 FY20252025-08-07EPS$0.36 vs $1.40-74.3%Rev$211.4M vs ——EODHD
- Q1 FY20252025-05-07EPS$0.69 vs $-0.07+100.0%Rev$197.1M vs ——EODHD
- Q4 FY20242025-02-25EPS$-0.55 vs $0.29-100.0%Rev$190.6M vs ——EODHD
- Q3 FY20242024-11-07EPS$1.34 vs $1.09+22.9%Rev$148.3M vs ——EODHD
- Q2 FY20242024-08-05EPS$1.02 vs $0.95+7.4%Rev$138.0M vs ——EODHD
- Q1 FY20242024-05-09EPS$1.21 vs $1.00+21.0%Rev$137.4M vs ——EODHD
- Q4 FY20232024-02-28EPS$1.00 vs $0.86+16.3%Rev$131.7M vs ——EODHD
- Q3 FY20232023-11-07EPS$1.27 vs $0.84+51.2%Rev$131.8M vs ——EODHD
- Q2 FY20232023-08-08EPS$1.28 vs $0.68+88.2%Rev$116.5M vs ——EODHD
- Q1 FY20232023-05-07EPS$1.17 vs $0.35+100.0%Rev$106.8M vs ——EODHD
- Q4 FY20222023-03-08EPS$0.76 vs $0.67+13.4%Rev$94.2M vs ——EODHD
- Q3 FY20222022-11-08EPS$0.64 vs $0.55+16.4%Rev$83.8M vs ——EODHD
- Q2 FY20222022-08-07EPS$0.13 vs $0.22-40.9%Rev$73.9M vs ——EODHD
- Q1 FY20222022-05-09EPS$-0.12 vs $0.09-100.0%Rev$64.5M vs ——EODHD
- Q4 FY20212022-03-14EPS$0.54 vs $0.74-27.0%Rev$60.9M vs ——EODHD
- Q3 FY20212021-10-31EPS$1.01 vs $0.70+44.3%Rev$52.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-06 | — | $2.00 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-07 | $2.05 | $1.30 | +57.8% | $237.5M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $2.33 | $2.04 | +14.2% | $247.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-06 | $2.04 | $1.76 | +15.9% | $227.8M | — | — | EODHD |
| Q2 FY2025 | 2025-08-07 | $0.36 | $1.40 | -74.3% | $211.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $0.69 | $-0.07 | +100.0% | $197.1M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.55 | $0.29 | -100.0% | $190.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-07 | $1.34 | $1.09 | +22.9% | $148.3M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $1.02 | $0.95 | +7.4% | $138.0M | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $1.21 | $1.00 | +21.0% | $137.4M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $1.00 | $0.86 | +16.3% | $131.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $1.27 | $0.84 | +51.2% | $131.8M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $1.28 | $0.68 | +88.2% | $116.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $1.17 | $0.35 | +100.0% | $106.8M | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $0.76 | $0.67 | +13.4% | $94.2M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $0.64 | $0.55 | +16.4% | $83.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $0.13 | $0.22 | -40.9% | $73.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.12 | $0.09 | -100.0% | $64.5M | — | — | EODHD |
| Q4 FY2021 | 2022-03-14 | $0.54 | $0.74 | -27.0% | $60.9M | — | — | EODHD |
| Q3 FY2021 | 2021-10-31 | $1.01 | $0.70 | +44.3% | $52.1M | — | — | EODHD |
Source: EODHD. ANIP reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ANIP's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 100% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.41 | $1.29 | +9.4% | -1.7% | -1.5% |
| Q4 FY2026 | $1.54 | $1.36 | +13.1% | -5.8% | -5.1% |
| Q3 FY2026 | $1.37 | $1.22 | +12.0% | -6.9% | -7.4% |
| Q2 FY2026 | $1.44 | $1.27 | +13.1% | -2.7% | -5.6% |
| Q1 FY2025 | $1.59 | $1.29 | +23.4% | -6.5% | -5.8% |
| Q4 FY2025 | $1.54 | $1.40 | +9.7% | -5.2% | -4.8% |
| Q3 FY2025 | $1.62 | $1.42 | +13.9% | -4.5% | -3.5% |
| Q2 FY2025 | $1.60 | $1.31 | +22.5% | -7.1% | -5.4% |
| Q1 FY2024 | $1.57 | $1.40 | +12.4% | -3.9% | -3.7% |
| Q4 FY2024 | $1.60 | $1.41 | +13.8% | -3.9% | -3.5% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Nikhil LalwaniCEO4 mo21 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • last call held guidance Q3 FY2026
- Stephen P CareyCFO4 mo16 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
- Muthusamy ShanmugamCOO4 mono recorded callsCurrentSample
COO since 2026 • 1/2 beats (50%) • last guidance raise Q2 FY2026
- Krista DavisSVP, CHIEF HR OFFICER4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
- Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS4 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last call held guidance Q1 FY2026
- Christopher MutzHEAD OF RARE DISEASE4 mo10 callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • guidance suspended Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ANIP.
$ curl https://api.spokenalpha.com/v1/companies/ANIPFAQ
Frequently asked about ANIP
Where can I find ANI PHARMACEUTICALS INC's (ANIP) earnings call transcripts?
Spoken Alpha indexes ANIP's earnings call transcripts at https://spokenalpha.com/companies/ANIP. Each call links to attributed speakers and parsed analyst Q&A. ANI PHARMACEUTICALS INC's own investor relations page is at https://investor.anipharmaceuticals.com/.
When was ANI PHARMACEUTICALS INC's most recent earnings call?
ANI PHARMACEUTICALS INC (ANIP) held its most recent earnings call on 2026-05-08, covering fiscal Q1 2026.
What sector is ANIP in?
ANI PHARMACEUTICALS INC (ANIP) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).